TNFRSF10A and familial pancreatic carcinoma: Indeed, compounds such as the recombinant ligand and agonistic monoclonal antibodies directed against DR4 and/or DR5 are being investigated within clinical trials [40], and low concentrations of bortezomib sensitize different cancer cells, including hepatoma, colon and pancreatic cancer cell lines for TRAIL-induced apoptosis [41].